» Articles » PMID: 26467269

The Clinical Course of Health Status and Association with Outcomes in Patients Hospitalized for Heart Failure: Insights from ASCEND-HF

Abstract

Aims: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge.

Methods And Results: A post-hoc analysis was performed of the ASCEND-HF trial. The EuroQOL five dimensions questionnaire (EQ-5D) was administered to study participants at baseline, 24 h, discharge/day 10, and day 30. EQ-5D includes functional dimensions mapped to corresponding utility scores (i.e. 0 = death and 1 = perfect health), and a visual analogue scale (VAS) ranging from 0 (i.e. 'worst imaginable health state') to 100 (i.e. 'best imaginable health state'). The association between baseline and discharge EQ-5D measurements and subsequent clinical outcomes including death and rehospitalization were assessed using multivariable logistic regression and Cox proportional hazards regression. A total of 6943 patients (97%) had complete EQ-5D data at baseline. Mapped utility and VAS scores (mean ± SD) increased over time, respectively, from 0.56 ± 0.23 and 45 ± 22 at baseline to 0.67 ± 0.26 and 58 ± 22 at 24 h and to 0.79 ± 0.20 and 68 ± 22 at discharge, and remained stable at day 30. Lower mapped utility scores at baseline [odds ratio (OR) per 0.1 decrease in utility score 1.03, 95% confidence interval (CI) 1.00-1.06] and discharge (OR 1.10, 95% CI 1.05-1.15) and VAS scores at baseline (OR per 10 point decrease 1.05, 95% CI 1.01-1.09) were significantly associated with increased risk of 30-day all-cause death or HF rehospitalization.

Conclusions: Patients hospitalized for HF had severely impaired health status at baseline and, although this improved substantially during admission, health status remained abnormal at discharge.

Citing Articles

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.

Kongmalai T, Prawjaeng J, Hadnorntun P, Leelahavarong P, Chaikledkaew U, Thakkinstian A Pharmacoecon Open. 2024; 9(1):69-81.

PMID: 39306816 PMC: 11717763. DOI: 10.1007/s41669-024-00526-2.


Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Lien P, Joshi M, Tice J, Agboola F, Nikitin D, Withanawasam V J Manag Care Spec Pharm. 2024; 30(6):517-527.

PMID: 38824625 PMC: 11144987. DOI: 10.18553/jmcp.2024.30.6.517.


The association in diabetic retinopathy and stroke finding from NHANES evidence.

Tang J, Huang P Int Ophthalmol. 2024; 44(1):170.

PMID: 38587685 DOI: 10.1007/s10792-024-03098-6.


Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry.

Rao V, Mentz R, Coniglio A, Kelsey M, Fudim M, Fonarow G Circ Heart Fail. 2022; 15(11):e009353.

PMID: 36378758 PMC: 9673180. DOI: 10.1161/CIRCHEARTFAILURE.121.009353.


In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.

Rao V, Shah A, McDermott J, Barnes S, Murray E, Kelsey M Circ Heart Fail. 2022; 16(2):e010158.

PMID: 36314130 PMC: 9974597. DOI: 10.1161/CIRCHEARTFAILURE.122.010158.


References
1.
Metra M, Cleland J, Weatherley B, Dittrich H, Givertz M, Massie B . Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. Eur J Heart Fail. 2010; 12(5):499-507. DOI: 10.1093/eurjhf/hfq021. View

2.
Hernandez A, OConnor C, Starling R, Reist C, Armstrong P, Dickstein K . Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009; 157(2):271-7. DOI: 10.1016/j.ahj.2008.07.031. View

3.
Lewis E, Pfeffer M, Feng A, Uno H, McMurray J, Toto R . Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011; 6(4):845-55. PMC: 3069378. DOI: 10.2215/CJN.06450710. View

4.
Metra M, OConnor C, Davison B, Cleland J, Ponikowski P, Teerlink J . Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J. 2011; 32(12):1519-34. DOI: 10.1093/eurheartj/ehr042. View

5.
OConnor C, Starling R, Hernandez A, Armstrong P, Dickstein K, Hasselblad V . Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011; 365(1):32-43. DOI: 10.1056/NEJMoa1100171. View